Physician profile
Patrick K Ryan
NPI 1336324169
$6,011.39
in general payments reported to CMS, 2019-2025
52 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $361 · 2021: $1,011 · 2022: $1,275 · 2023: $1,306 · 2024: $1,126 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $897.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $732.45 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $464.73 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $337.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $310.58 | 2019-2022 | |
| Amgen INC. | $303.02 | 2019-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $267.57 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $234.14 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $207.59 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $187.82 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $139.26 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $129.86 | 2022-2024 | Verquvo, Belsomra |
| Sumitomo Pharma America, INC. | $121.71 | 2023-2024 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $116.62 | 2019 | |
| Horizon Therapeutics Plc | $109.90 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.